| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2021-09-24 20:31:35 UTC |
|---|
| Update Date | 2021-09-24 20:31:36 UTC |
|---|
| HMDB ID | HMDB0304875 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Zanubrutinib |
|---|
| Description | Zanubrutinib, also known as brukinsa, belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group. Based on a literature review a significant number of articles have been published on Zanubrutinib. |
|---|
| Structure | NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1 InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 7-(1-Acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide | HMDB | | Brukinsa | HMDB | | (7S)-2-(4-Phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide | MeSH |
|
|---|
| Chemical Formula | C27H29N5O3 |
|---|
| Average Molecular Weight | 471.561 |
|---|
| Monoisotopic Molecular Weight | 471.227039814 |
|---|
| IUPAC Name | (7S)-2-(4-phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidine-3-carboxamide |
|---|
| Traditional Name | (7S)-2-(4-phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidine-3-carboxamide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1 |
|---|
| InChI Identifier | InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1 |
|---|
| InChI Key | RNOAOAWBMHREKO-QFIPXVFZSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylethers |
|---|
| Direct Parent | Diphenylethers |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylether
- Phenylpyrazole
- Diaryl ether
- Pyrimidinecarboxamide
- Pyrazolopyrimidine
- N-acyl-piperidine
- Phenoxy compound
- Pyrazole-4-carboxamide
- Phenol ether
- Secondary aliphatic/aromatic amine
- Pyrimidine
- Piperidine
- Acrylic acid or derivatives
- Heteroaromatic compound
- Vinylogous amide
- Tertiary carboxylic acid amide
- Pyrazole
- Azole
- Primary carboxylic acid amide
- Carboxamide group
- Amino acid or derivatives
- Azacycle
- Organoheterocyclic compound
- Secondary amine
- Ether
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 14.0039 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.7 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1985.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 186.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 166.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 171.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 103.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 462.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 449.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 149.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 898.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 433.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1394.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 295.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 351.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 302.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 303.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 52.8 seconds | 40023050 |
Predicted Kovats Retention IndicesDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Zanubrutinib,1TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4595.3 | Semi standard non polar | 33892256 | | Zanubrutinib,1TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3462.2 | Standard non polar | 33892256 | | Zanubrutinib,1TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5749.8 | Standard polar | 33892256 | | Zanubrutinib,1TMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4521.6 | Semi standard non polar | 33892256 | | Zanubrutinib,1TMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3161.7 | Standard non polar | 33892256 | | Zanubrutinib,1TMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5641.0 | Standard polar | 33892256 | | Zanubrutinib,2TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(=O)N[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4471.2 | Semi standard non polar | 33892256 | | Zanubrutinib,2TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(=O)N[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3264.2 | Standard non polar | 33892256 | | Zanubrutinib,2TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(=O)N[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5260.4 | Standard polar | 33892256 | | Zanubrutinib,2TMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4539.1 | Semi standard non polar | 33892256 | | Zanubrutinib,2TMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3548.0 | Standard non polar | 33892256 | | Zanubrutinib,2TMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5573.8 | Standard polar | 33892256 | | Zanubrutinib,3TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4436.2 | Semi standard non polar | 33892256 | | Zanubrutinib,3TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3387.7 | Standard non polar | 33892256 | | Zanubrutinib,3TMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C)C3=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5078.1 | Standard polar | 33892256 | | Zanubrutinib,1TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4801.1 | Semi standard non polar | 33892256 | | Zanubrutinib,1TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3625.7 | Standard non polar | 33892256 | | Zanubrutinib,1TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5776.7 | Standard polar | 33892256 | | Zanubrutinib,1TBDMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4719.0 | Semi standard non polar | 33892256 | | Zanubrutinib,1TBDMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3459.1 | Standard non polar | 33892256 | | Zanubrutinib,1TBDMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5717.4 | Standard polar | 33892256 | | Zanubrutinib,2TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(=O)N[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4803.2 | Semi standard non polar | 33892256 | | Zanubrutinib,2TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(=O)N[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3768.6 | Standard non polar | 33892256 | | Zanubrutinib,2TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(=O)N[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5356.8 | Standard polar | 33892256 | | Zanubrutinib,2TBDMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4858.1 | Semi standard non polar | 33892256 | | Zanubrutinib,2TBDMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 3876.0 | Standard non polar | 33892256 | | Zanubrutinib,2TBDMS,isomer #2 | C=CC(=O)N1CCC([C@@H]2CCNC3=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5551.8 | Standard polar | 33892256 | | Zanubrutinib,3TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4882.5 | Semi standard non polar | 33892256 | | Zanubrutinib,3TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 4077.5 | Standard non polar | 33892256 | | Zanubrutinib,3TBDMS,isomer #1 | C=CC(=O)N1CCC([C@@H]2CCN([Si](C)(C)C(C)(C)C)C3=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1 | 5166.2 | Standard polar | 33892256 |
|
|---|